Idorsia is a high-potential biopharmaceutical company, with an experienced team of over 1,200 highly qualified professionals, a full R&D pipeline, state-of-the-art facilities, and a strong balance sheet – the ideal constellation for bringing successful medicines to the market.
We began our operations after demerging from Actelion following its acquisition by Johnson & Johnson in 2017. At that time, approximately 650 talented and engaged employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets.
Idorsia is specialized in the discovery and development of small molecules, with the aim of transforming the horizon of therapeutic options. We have a broad, diversified and balanced development pipeline, covering multiple therapeutic areas.
2017
Served areaWorldwide
Headcount1,200
HeadquartersHegenheimermattweg 91, 4123 Allschwil – Switzerland
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
11.05.22 | None | Non-Executive member | Buy | CHF 98,179.90 |
10.05.22 | None | Non-Executive member | Buy | CHF 109,660.30 |
CH0363463438
LEI506700XOVZUB107S5720
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.